Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections

Cornea

Volumn 31, Issue 8, 2012, Pages 900-906

  Brown Elliott, Barbara A ^a   Mann, Linda B ^a   Hail, Daymon ^a   Whitney, Clayton ^b   Wallace Jr , Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Trinity Mother Frances Clinic Eye Center   (United States)

Author keywords

besifloxacin; mycobacteria; ophthalmic

Indexed keywords

AMIKACIN; AZITHROMYCIN; BESIFLOXACIN; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; HEAT SHOCK PROTEIN 65; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL EYE INFECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHAPERONIN 60; EYE INFECTIONS, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S;

EID: 84863780686     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f8bb9     Document Type: Article

References (47)

1. Ford JG, Huang AJ, Pflugfelder SC, et al. Nontuberculous mycobacterial keratitis in South Florida. Ophthalmology. 1998;105:1652-1658.
2. Holmes GP, Bond GB, Fader RC, et al. A cluster of cases of Mycobacterium szulgai keratitis that occurred after laser-assisted in situ keratomileusis. Clin Infect Dis. 2002;34:1039-1046.
3. Huang SC, Soong HK, Chang JS, et al. Non-tuberculous mycobacterial keratitis: A study of 22 cases. Br J Ophthalmol. 1996;80:962-968.
4. Bullington RH Jr, Lanier JD, Font RL. Nontuberculous mycobacterial keratitis. Report of two cases and review of the literature. Arch Ophthalmol. 1992;110:519-524.
5. Sudesh S, Cohen EJ, Schwartz LW, et al. Mycobacterium chelonae infection in a corneal graft. Arch Ophthal. 2000;118:294-295.
6. Klapper SR, Patrinely JR, Kaplan SL, et al. Atypical mycobacterial infection of the orbit. Ophthalmology. 1995;102:1536-1541.
7. Klapper SR, Patrinely JR. Periocular atypical mycobacterial infections. Ophthalmology. 1999;106:1640-1641.
8. Garg P, Bansal AK, Sharma S, et al. Bilateral infectious keratitis after laser in situ keratomileusis: A case report and review of literature. Ophthalmology. 2001;108:121-125.
9. Sampaio JL, Junior DN, de Freitas D, et al. An outbreak of keratitis caused by Mycobacterium immunogenum. J Clin Microbiol. 2006;44: 3201-3207.
10. Winthrop KL, Steinberg EB, Holmes G, et al. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. Am J Ophthalmol. 2003;135:223-224.
11. Chandra NS, Torres MF, Winthrop KL, et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am J Ophthalmol. 2001;132:819-830.
12. Solomon A, Karp CL, Miller D, et al. Mycobacterium interface keratitis after laser in situ keratomileusis. Ophthalmology. 2001;108:2201-2208.
13. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110:276-285.
14. Chung MS, Goldstein MH, Driebe WT Jr, et al. Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. Am J Ophthalmol. 2000;129:382-384.
15. Hyon JY, Joo MJ, Hose S, et al. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Arch Ophthalmol. 2004;122:1166-1169.
16. Steingrube VA, Gibson JL, Brown BA, et al. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria [Erratum appears in J Clin Microbiol. 1995;33:1686]. J Clin Microbiol. 1995;33:149-153.
17. Telenti A, Marchesi F, Balz M, et al. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31:175-178.
18. Yakrus MA, Hernandez SM, Floyd MM, et al. Comparison of methods for identification of Mycobacterium abscessus and M. chelonae isolates. J Clin Microbiol. 2001;39:4103-4110.
19. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552-3560.
20. Hall L, Doerr KA, Wohlfiel SL, et al. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J Clin Microbiol. 2003;41:1447-1453.
21. Simmon KE, Low YY, Brown-Elliott BA, et al. Phylogenetic analysis of Mycobacterium aurum and Mycobacterium neoaurum with redescription of M. aurum culture collection strains. Int J Syst Evol Microbiol. 2009;59 (pt 6):1371-1375.
22. Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard-Second Edition. Vol 31. Wayne, PA: Clinical and Laboratory Standards Institute; 2011; CLSI document M24-A2.
23. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 15th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2005; CLSI document M100-S15.
24. Swenson JM, Thornsberry C, Silcox VA. Rapidly growing mycobacteria: Testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother. 1982;22:186-192.
25. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716-746.
26. Silcox VA, Good RC, Floyd MM. Identification of clinically significant Mycobacterium fortuitum complex isolates. J Clin Microbiol. 1981;14: 686-691.
27. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae subspecies chelonae-importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992;166:405-412.
28. Patel JB, Leonard DG, Pan X, et al. Sequence-based identification of Mycobacterium species using the MicroSeq 500 16S rDNA bacterial identification system. J Clin Microbiol. 2000;38:246-251.
29. Leao SC, Tortoli E, Viana-Niero C, et al. Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol. 2009;47:2691-2698.
30. Wallace RJ Jr, Steele LC, Labidi A, et al. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J Infect Dis. 1989;160:281-288.
31. Deschênes J, Wade NK, Lalonde R. Tuberculosis and atypical mycobacteria. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology on CD ROM, 2006 Edition. Vol 58. Baltimore, MD: Lippincott Williams & Wilkins; 2006:1-14.
32. Wallace RJ Jr, Musser JM, Hull SI, et al. Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis. 1989;159:708-716.
33. Franklin DJ, Starke JR, Brady MT, et al. Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: A new clinical entity? Am J Otol. 1994;15:313-320.
34. Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008;61:111-116.
35. Nash KA, Zhang Y, Brown-Elliott BA, et al. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005;55:170-177.
36. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367-1376.
37. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987;135:1007-1014.
38. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993;147:1271-1278.
39. Roussel TJ, Stern WH, Goodman DF, et al. Postoperative mycobacterial endophthalmitis. Am J Ophthalmol. 1989;107:403-406.
40. Gilbert ML, Wilhelmus KR, Osato MS. Comparative bioavailability and efficacy of fortified topical tobramycin. Invest Ophthalmol Vis Sci. 1987; 28:881-885.
41. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmololgy. 1996;103:1854-1863.
42. Cremades R, Santos A, Rodríguez JC, et al. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J Chemother. 2008;20:43-47.
43. Helm CJ, Holland GN, Lin R, et al. Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model. Am J Ophthalmol. 1993;116:700-707.
44. Hooper DC. Mechanisms of quinolone resistance. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. 3rd ed. Washington, DC: ASM Press; 2003.
45. Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;4:335-344.
46. Arnold DR, Granvil CP, Ward KW. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry.
47. Zhang JZ, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res. 2008;33:923-932.